Michio Iwata
Overview
Explore the profile of Michio Iwata including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
150
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iida M, Kuniki Y, Yagi K, Goda M, Namba S, Takeshita J, et al.
Commun Med (Lond)
. 2024 Jul;
4(1):154.
PMID: 39075184
Background: Combination therapy can offer greater efficacy on medical treatments. However, the discovery of synergistic drug combinations is challenging. We propose a novel computational method, SyndrumNET, to predict synergistic drug...
2.
Yoshimura H, Takeda Y, Shirai Y, Yamamoto M, Nakatsubo D, Amiya S, et al.
J Allergy Clin Immunol
. 2024 Mar;
153(5):1268-1281.
PMID: 38551536
Background: Novel biomarkers (BMs) are urgently needed for bronchial asthma (BA) with various phenotypes and endotypes. Objective: We sought to identify novel BMs reflecting tissue pathology from serum extracellular vesicles...
3.
Hamano M, Nakamura T, Ito R, Shimada Y, Iwata M, Takeshita J, et al.
Bioinformatics
. 2024 Jan;
40(2).
PMID: 38273708
Motivation: Direct reprogramming (DR) is a process that directly converts somatic cells to target cells. Although DR via small molecules is safer than using transcription factors (TFs) in terms of...
4.
Rashid M, Hamano M, Iida M, Iwata M, Ko T, Nomura S, et al.
Biosystems
. 2024 Jan;
236:105122.
PMID: 38199520
The integration of multiple omics data promises to reveal new insights into the pathogenic mechanisms of complex human diseases, with the potential to identify avenues for the development of targeted...
5.
Iwata M, Mutsumine H, Nakayama Y, Suita N, Yamanishi Y
Nat Comput Sci
. 2024 Jan;
2(11):758-770.
PMID: 38177364
Genome-wide identification of single-cell transcriptomic responses of drugs in various human cells is a challenging issue in medical and pharmaceutical research. Here we present a computational method, tensor-based imputation of...
6.
Yamanaka C, Uki S, Kaitoh K, Iwata M, Yamanishi Y
Mol Inform
. 2023 Jul;
42(8-9):e2300064.
PMID: 37475603
Computational de novo drug design is a challenging issue in medicine, and it is desirable to consider all of the relevant information of the biological systems in a disease state....
7.
Iwata M, Kosai K, Ono Y, Oki S, Mimori K, Yamanishi Y
NPJ Syst Biol Appl
. 2022 Nov;
8(1):44.
PMID: 36344521
Drugs are expected to recover the cell system away from the impaired state to normalcy through disease treatment. However, the understanding of gene regulatory machinery underlying drug activity or disease...
8.
Nakamura T, Iwata M, Hamano M, Eguchi R, Takeshita J, Yamanishi Y
Bioinformatics
. 2022 Sep;
38(Suppl_2):ii99-ii105.
PMID: 36124791
Motivation: Direct cell conversion, direct reprogramming (DR), is an innovative technology that directly converts source cells to target cells without bypassing induced pluripotent stem cells. The use of small compounds...
9.
Namba S, Iwata M, Yamanishi Y
Bioinformatics
. 2022 Jun;
38(Suppl 1):i68-i76.
PMID: 35758779
Motivation: A critical element of drug development is the identification of therapeutic targets for diseases. However, the depletion of therapeutic targets is a serious problem. Results: In this study, we...
10.
Eguchi R, Hamano M, Iwata M, Nakamura T, Oki S, Yamanishi Y
Bioinformatics
. 2022 May;
38(10):2839-2846.
PMID: 35561200
Motivation: Direct reprogramming involves the direct conversion of fully differentiated mature cell types into various other cell types while bypassing an intermediate pluripotent state (e.g. induced pluripotent stem cells). Cell...